Christina Gerde participates in European Liquid Biopsy Society event Nov 4

by PALEMA | 9 December, 2025 | PALEMA in the media

This is a presentation by Christina Gerde for about 80 experts on liquid biopsy from November 4, 2025 in Madrid. It is about PALEMA and our needs.

ELBS is a European research and collaboration network consisting of academic institutions, university hospitals and diagnostic and pharmaceutical companies. The aim of the organization is to advance the use of liquid biopsy – diagnostic tests based on blood or other body fluids – so that they soon become part of clinical routine and thus benefit cancer patients.

After 4 hours, 24 minutes and 45 seconds into the recording on youtube, Christina’s presentation on PALEMA is the only patient presentation made, last in the program.

Christina Gerde participates in European Liquid Biopsy Society event Nov 4

Blåljuscancer (R)

Palema Redaktion

Välkommen att kontakta PALEMAs redaktion om du har förslag på artiklar eller synpunkter på artiklar vi skrivit.

Observera att detta inte är ett debattforum, vill du debattera med andra hänvisar vi till våra slutna Facebookgrupper.

Dela – Mejla – Skriv ut:

Share- Email – Print:

Vi tackar våra sponsorer för deras oumbärliga stöd!

Weekend Webbexperterna

Wavebox

Weekend Webbexperterna

Mediemerah

Fler nyheter:

More news:

Interview

Emergency cancer, Pancreatic cancer, Research

The patients perspective: Interview with the Swedish cancer association PALEMA

Biotech company Alligator Bioscience AB interviews PALEMA in its annual report for 2025 and discusses, among other things, Emergency cancer (Blåljuscancer), medical needs, clinical studies and what message PALEMA wants to send to decision-makers and healthcare.

1 April, 2026

Analysis

Pancreatic cancer, Research

Study of breath test for pancreatic cancer is being tested

This exciting step forward follows a two-year clinical trial, in which researchers at Imperial College London analyzed over 700 breath samples from people with and without pancreatic cancer, as well as from people with other conditions affecting the pancreas.

23 January, 2026

Foxglove flower photo: Jessica Cortez

Pancreatic cancer, Research

18th century medicine being tested against deadly cancer

An 18th century remedy could be a new weapon in the fight against one of the most deadly cancers. Researchers in Skövde, Sweden, together with Skaraborg Hospital, are now starting a clinical trial to investigate whether the heart medicine digitoxin, originally extracted from the foxglove flower, can be used against pancreatic cancer.

10 November, 2025

Cells

Pancreatic cancer, Research

Tumor cells exploit damaged pancreatic tissue

Pancreatic cancer is one of the most aggressive cancers. A new study from Karolinska Institutet in collaboration with the Department of Pathology at Karolinska University Hospital shows that tumor cells grow not only in the connective tissue-rich environment typical of the disease, but also in damaged parts of the pancreas where normal tissue has been altered. The findings may provide new insights into tumor development and treatment.

10 November, 2025

Interview

Emergency cancer, Pancreatic cancer, Research

The patients perspective: Interview with the Swedish cancer association PALEMA

Biotech company Alligator Bioscience AB interviews PALEMA in its annual report for 2025 and discusses, among other things, Emergency cancer (Blåljuscancer), medical needs, clinical studies and what message PALEMA wants to send to decision-makers and healthcare.

1 April, 2026

Analysis

Pancreatic cancer, Research

Study of breath test for pancreatic cancer is being tested

This exciting step forward follows a two-year clinical trial, in which researchers at Imperial College London analyzed over 700 breath samples from people with and without pancreatic cancer, as well as from people with other conditions affecting the pancreas.

23 January, 2026

Foxglove flower photo: Jessica Cortez

Pancreatic cancer, Research

18th century medicine being tested against deadly cancer

An 18th century remedy could be a new weapon in the fight against one of the most deadly cancers. Researchers in Skövde, Sweden, together with Skaraborg Hospital, are now starting a clinical trial to investigate whether the heart medicine digitoxin, originally extracted from the foxglove flower, can be used against pancreatic cancer.

10 November, 2025

Cells

Pancreatic cancer, Research

Tumor cells exploit damaged pancreatic tissue

Pancreatic cancer is one of the most aggressive cancers. A new study from Karolinska Institutet in collaboration with the Department of Pathology at Karolinska University Hospital shows that tumor cells grow not only in the connective tissue-rich environment typical of the disease, but also in damaged parts of the pancreas where normal tissue has been altered. The findings may provide new insights into tumor development and treatment.

10 November, 2025

Pin It on Pinterest